Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SINOVAC BIOTECH LTD.

(SVA)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Sector news Biopharmaceuticals
05:36aMizuho Securities Cuts Biogen's Price Target to $270 From $300, Citing Aduhelm Sales Es..
MT
10/25SAMSUNG BIOLOGICS : S.Korea approves Moderna's COVID-19 vaccine produced by Samsung Biolog..
RE
10/25Hong Kong shares close flat as gains in energy, materials offset realty losses
RE
10/25Shanghai stocks boosted by environmental protection firms; property stocks down
RE
10/22BIOGEN : Canaccord Genuity Adjusts Biogen PT to $390 From $423, Maintains Buy Rating
MT
10/22BB BIOTECH AG : BB Biotech: i ricavi -2-
DJ
10/22PRESS RELEASE : BB Biotech: Gains realized -2-
DJ
10/21BIOGEN : UBS Adjusts Price Target on Biogen to $406 From $405, Maintains Buy Rating
MT
10/21BIOGEN : Cowen Adjusts Biogen PT to $375 From $450, Maintains Outperform Rating
MT
10/21BIOGEN : JPMorgan Adjusts Biogen's Price Target to $324 From $425, Maintains Neutral Ratin..
MT
10/21BIOGEN : Morgan Stanley Adjusts Biogen's Price Target to $440 From $447, Maintains Overwei..
MT
10/21BIOGEN : Oppenheimer Adjusts Price Target on Biogen to $390 from $450, Keeps Outperform Ra..
MT
10/21BIOGEN : Needham Adjusts Price Target on Biogen to $386 from $398, Keeps Buy Rating
MT
10/21BIOGEN : RBC Cuts Price Target on Biogen to $295 From $325, Maintains Sector Perform Ratin..
MT
10/21BIOGEN : Wedbush Lowers Price Target on Biogen to $261 From $297, Sees 'More Significant I..
MT
10/20BIOGEN : Third-Quarter Results Fall as Alzheimer's Drug Sales Miss Street Views; Full-Year..
MT
10/20BIOGEN : UBS Adjusts Price Target on Biogen to $405 From $442, Maintains Buy Rating
MT
10/20BIOGEN : Q3 Non-GAAP Earnings, Revenue Drop; Company Boosts FY Outlook
MT
10/20Biogen Raises Full-Year Guidance
DJ
10/20Biogen Inc. Updates Earnings Guidance for the Full Year of 2021
CI
10/20Biogen Inc. Reports Unaudited Impairment Charges for the Three Months Ended September 3..
CI
10/20Tranche Update on Biogen Inc.'s Equity Buyback Plan announced on October 21, 2020.
CI
10/20EARNINGS REACTION HISTORY : Biogen Inc, 33.3% Follow-Through Indicator, 4.8% Sensitive
MT
10/20Biogen 3Q Results Beat Expectations; Alzheimer's Drug Aduhelm Posts Sales of $300,000
DJ
10/19BIOGEN : sales face pressure from slow uptake of Alzhiemer's drug
RE
10/19BIOGEN : Aduhelm Drug for Alzheimer's Remains in Focus Ahead of Q3 Results, Oppenheimer Sa..
MT
10/19SAGE THERAPEUTICS : Biogen Submit Depression Drug Zuranolone New Drug Application to FDA
MT
10/19BIOGEN : Needham Trims Price Target on Biogen to $398 From $400, Maintains Buy Rating
MT
10/19Sage Therapeutics, Inc. and Biogen Inc. Announce Plans to Submit a New Drug Application..
CI
10/19Sage Therapeutics, Biogen to Seek FDA Approval of Zuranolone in 2nd Half of 2022
DJ
10/19S.Korean stocks rebound on tech boost, easing China property woes
RE
10/18CSL Limited Highlights Progress from Its Novel Pipeline That Spans Six Therapeutic Area..
CI
10/18CSL Limited Announces New Strategic Collaboration with Walter and Eliza Hall Institute ..
CI
10/18US Stocks Extend Winning Streak as Factory Output Posts Surprise Drop
MT
10/18CLOSE UPDATE : US Stocks Start Week Mostly Higher Ahead of Next Earnings Batch Even as Fac..
MT
10/18Equities Mixed Midday Following Surprise Dip in Industrial Production
MT
10/18MIDDAY REPORT : US Stocks Mixed Following Surprise Dip in Industrial Production; Treasury ..
MT
10/18Ionis Pharma Shares Drop 12% After Tofersen Study Misses Primary Endpoint
DJ
10/18IONIS PHARMACEUTICALS : Partner Biogen Says Tofersen Study Failed to Meet Primary Goal; Sh..
MT
10/18South Korean Stocks Slip on Slower Economy Growth in China, Highest Oil Prices in Years
MT
10/18CHINA EVERGRANDE : Hong Kong shares close higher despite China's weak growth data
RE
10/18BIOGEN : Tofersen Misses Primary Endpoint But Still Shows Signs of Reduced Disease Progres..
MT
10/17Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Ext..
CI
10/17BIOGEN : trial of ALS drug fails main goal, but company says data are encouraging
RE
10/15BIOGEN : Stifel Adjusts Biogen's Price Target to $344 from $430, Keeps Buy Rating
MT
10/15BIOGEN : Cantor Fitzgerald Adjusts Price Target on Biogen to $327 From $427, Maintains Neu..
MT
10/15South Korean Stocks Close Higher on Chip Shares' Gains; Samsung, SK Hynix Move Markets
MT
10/15Analysis-Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
RE
10/15CSL : Reaffirms Commitment to Manufacture 50 Million Doses of AstraZeneca Vaccine
MT
10/15Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
RE
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on SINOVAC BIOTECH LTD.
11/29/21
Upcoming sector events